DOI: 10.36347/sjmcr.2021.v09i06.007

Pages: 640-644

Several patients with pneumonia-like symptoms of unknown cause were found linked to the wholesale market in Wuhan, China, in December 2019. The World Health Organization announced on March 11th, 2020, that the outbreak of “Corona Virus Disease 2019” (COVID-19) has become pandemic. At present, we are going through the second wave of infection. To date, no evidence consistently supports any treatment for COVID-19 patients, so identifying new therapeutic options seems beneficial in the management of this disease. This study aimed to report the role of piperacillin-tazobactam antibiotics in patients of COVID-19 disease with bacterial co-infection. In the present case report, the COVID-19 positive patient’s clinic-biochemical examination along with HR-CT scan were analyze. Furthermore, along with various symptomatic medications, the role Piperacillin-tazobactam was analyzed after administration. Results show that after administering intravenous piperacillin-tazobactam tothe patient, the patient's general condition improves. The patient’s routine blood investigations were to come to normal limits and breaths on normal roomair with SpO2 96%.Based on improvement in patient general condition, oxygen saturation, and in routine blood investigation, we can say that there is some hidden role of intravenous piperacillin-tazobactam injection in the management of COVID-19. Alternatively, we can say that we can decrease the severity of COVID-19 infection by inhibiting the bacterial co-infection. Piperacillin-tazobactam might be useful in the early stages of SARS-CoV-2 infection and the case of bacterial co-infection, although further research is needed to assess the role of piperacillin/ tazobactam in COVID-19 infection.